# RAB26 promotes prostate cancer progression via the MAPK/ERK-TWIST1 signaling axis

## TL;DR

RAB26 promotes prostate cancer progression by activating the MAPK/ERK-TWIST1 pathway, leading to increased cancer cell aggression and poor patient outcomes.

## Contribution

This study identifies RAB26 as a novel driver of prostate cancer progression through the MAPK/ERK-TWIST1 signaling axis.

## Key findings

- High RAB26 expression correlates with advanced prostate cancer stages and poor prognosis.
- RAB26 promotes cancer cell proliferation, migration, invasion, and stemness in vitro.
- RAB26 activates TWIST1 via promoter interaction, inducing epithelial–mesenchymal transition.

## Abstract

RAB26 is important in the regulation of membrane trafficking and cell motility. Recently, RAB26 has received increasing attention in cancer research. However, the functional role of RAB26 in prostate cancer (PCa) remains to be elucidated. Single-cell RNA sequencing data (GSE141445) analysis indicated that RAB26 was widely expressed in PCa cells, especially in luminal cells and basal cells. High RAB26 expression in patients was found to be significantly associated with advanced pathological stage, Gleason score, and poor prognosis. Furthermore, our experimental results showed that RAB26 promoted the proliferation, migration, and invasion of PCa cells, as well as influenced the stemness of PCa cells in vitro. Besides, the transcription sequence indicated that RAB26 might promote the metastatic potential of PCa by promoting epithelial–mesenchymal transition through cascades of MAPK/ERK pathways. Finally, we found that RAB26 activated TWIST1 expression and consequently induced epithelial–mesenchymal transition, based on its interaction with the TWIST1 promoter. In conclusion, RAB26 promotes the aggressive progression of PCa and stemness of tumor cells, which is an independent biomarker for the prognosis of PCa.